BR0011880A - Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica - Google Patents

Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica

Info

Publication number
BR0011880A
BR0011880A BR0011880-0A BR0011880A BR0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A
Authority
BR
Brazil
Prior art keywords
compound
treatment
obesity
conditions associated
pharmaceutical composition
Prior art date
Application number
BR0011880-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David John Heal
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BR0011880A publication Critical patent/BR0011880A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0011880-0A 1999-06-24 2000-06-16 Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica BR0011880A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
BR0011880A true BR0011880A (pt) 2002-03-19

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011880-0A BR0011880A (pt) 1999-06-24 2000-06-16 Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica

Country Status (21)

Country Link
EP (1) EP1187606A1 (zh)
JP (1) JP2003503349A (zh)
KR (1) KR20020015357A (zh)
CN (1) CN1358092A (zh)
AU (1) AU5533200A (zh)
BG (1) BG106180A (zh)
BR (1) BR0011880A (zh)
CA (1) CA2375972A1 (zh)
CZ (1) CZ20014613A3 (zh)
GB (1) GB9914744D0 (zh)
HK (1) HK1049278A1 (zh)
HU (1) HUP0201878A3 (zh)
IL (1) IL147079A0 (zh)
MX (1) MXPA01012936A (zh)
NO (1) NO20016224L (zh)
PL (1) PL352402A1 (zh)
RU (1) RU2229289C2 (zh)
SK (1) SK18242001A3 (zh)
TR (1) TR200103699T2 (zh)
WO (1) WO2001000205A1 (zh)
ZA (1) ZA200109989B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
JP2010503709A (ja) * 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
PL352402A1 (en) 2003-08-25
HUP0201878A3 (en) 2005-04-28
RU2229289C2 (ru) 2004-05-27
CZ20014613A3 (cs) 2003-04-16
NO20016224D0 (no) 2001-12-19
ZA200109989B (en) 2003-02-26
AU5533200A (en) 2001-01-31
HK1049278A1 (zh) 2003-05-09
NO20016224L (no) 2002-02-12
TR200103699T2 (tr) 2002-04-22
IL147079A0 (en) 2002-08-14
MXPA01012936A (es) 2004-04-21
GB9914744D0 (en) 1999-08-25
SK18242001A3 (sk) 2003-02-04
WO2001000205A1 (en) 2001-01-04
EP1187606A1 (en) 2002-03-20
JP2003503349A (ja) 2003-01-28
BG106180A (en) 2002-08-30
KR20020015357A (ko) 2002-02-27
CN1358092A (zh) 2002-07-10
HUP0201878A2 (hu) 2003-08-28
CA2375972A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
GEP20043324B (en) Purine Derivatives
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
BR0113496A (pt) Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica
MY132705A (en) Novel compounds with analgesic effect
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
CA2274074A1 (en) Novel compounds with analgesic effect
DK0503440T3 (da) Sumatriptanholdige lægemidler
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR0010938A (pt) Derivados da 13-metil eritromicina
SE9900961D0 (sv) Novel compounds
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
BR9915480A (pt) Azalìdeos de 13 membros e a sua utilização como agentes antibióticos
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
TR200103144T2 (tr) Yeni bileşikler
GEP20043231B (en) Resorcinol Composition
AP9801235A0 (en) Erythromycin derivatives.

Legal Events

Date Code Title Description
PC Transfer

Owner name: ABBOTT GMBH & CO. KG (DE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH (DE)

B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.